What Oxyntomodulin is
Oxyntomodulin is an endogenous gut peptide with both GLP-1 and glucagon-related signaling activity in appetite and metabolic regulation.
Oxyntomodulin is grouped under Fat Loss + GLP-1s / Endogenous / Biology on PeptideFactCheck because it matters because it helps explain where some of the dual-agonist obesity-drug logic comes from.
The useful starting point is to separate the molecule itself from the internet story around it. It matters because it helps explain where some of the dual-agonist obesity-drug logic comes from.
Why people keep looking it up
It matters because it helps explain where some of the dual-agonist obesity-drug logic comes from.
Oxyntomodulin is an endogenous gut peptide with both GLP-1 and glucagon-related signaling activity in appetite and metabolic regulation.
Oxyntomodulin tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucagon receptor, and satiety signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Real biology plus some human work, but still mainly a mechanism-reference entry.
Human physiology work exists, but endogenous biology should not be mistaken for an approved commercial peptide product.
The pathway rationale is well aligned with incretin and glucagon biology.
Why this page carries the current tier: Real biology plus some human work, but still mainly a mechanism-reference entry.
The current seed trail for Oxyntomodulin is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
Endogenous hormone biology is informative, but product-level conclusions require separate evidence.
Oxyntomodulin is primarily an endogenous biology entry in this library rather than an FDA-approved drug.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Oxyntomodulin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Oxyntomodulin is CID 16144019. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16144019
- Formula
- C192H295N59O60S
- Molecular weight
- 4422
- InChIKey
- PXZWGQLGAKCNKD-DPNMSELWSA-N
Matched synonyms include Glicentin (33-69), RefChem:928406, DTXSID001055490, 62340-29-8, LV7ELH7V16, Oxyntomodulin, Proglucagon (33-69), V2R9I80984.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Oxyntomodulin returns 10 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Oxyntomodulin returns 513 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.